NasdaqGS - Delayed Quote USD
Karyopharm Therapeutics Inc. (KPTI)
5.12
-0.20
(-3.67%)
At close: 4:00:00 PM EDT
5.12
0.00
(0.00%)
After hours: 4:00:09 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -4 | -2.96 | -8.83 | -3.03 |
| Low Estimate | -4.72 | -4.16 | -10.67 | -3.2 |
| High Estimate | -3.47 | -1.33 | -7.33 | -2.77 |
| Year Ago EPS | -4.34 | -3.9 | -18.44 | -8.83 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 37.92M | 38.73M | 147.43M | 166.8M |
| Low Estimate | 31.23M | 37.13M | 141.41M | 154.31M |
| High Estimate | 45M | 40M | 155M | 188.64M |
| Year Ago Sales | 42.79M | 38.78M | 145.24M | 147.43M |
| Sales Growth (year/est) | -11.36% | -0.13% | 1.51% | 13.13% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -4.47 | -3.92 | -4.03 | -3.09 |
| EPS Actual | -4.34 | -3.9 | -3.6 | -2.77 |
| Difference | 0.13 | 0.02 | 0.43 | 0.32 |
| Surprise % | 2.80% | 0.64% | 10.71% | 10.32% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -4 | -2.96 | -8.83 | -3.03 |
| 7 Days Ago | -3.55 | -2.93 | -11.18 | -8.21 |
| 30 Days Ago | -3.55 | -2.93 | -11.18 | -8.21 |
| 60 Days Ago | -3.55 | -2.94 | -12.85 | -8.21 |
| 90 Days Ago | -1.55 | -3.39 | -11.53 | -6.45 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 2 | 3 |
| Up Last 30 Days | 1 | 1 | 2 | 3 |
| Down Last 7 Days | -- | 2 | 1 | -- |
| Down Last 30 Days | 2 | 2 | 1 | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| KPTI | 7.85% | 24.06% | 52.12% | 65.67% |
| S&P 500 | 13.32% | 2.67% | 7.78% | 13.75% |
Upgrades & Downgrades
| Maintains | RBC Capital: Outperform to Outperform | 5/13/2025 |
| Maintains | Barclays: Overweight to Overweight | 5/13/2025 |
| Maintains | Baird: Outperform to Outperform | 5/13/2025 |
| Maintains | Baird: Outperform to Outperform | 3/3/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/26/2025 |
| Reiterates | RBC Capital: Outperform to Outperform | 2/20/2025 |
Related Tickers
MGNX MacroGenics, Inc.
1.5900
+0.63%
MRSN Mersana Therapeutics, Inc.
0.3850
+13.20%
FGEN FibroGen, Inc.
0.3136
+2.48%
HRTX Heron Therapeutics, Inc.
1.9200
-2.54%
CHRS Coherus BioSciences, Inc.
0.8000
+5.12%
VSTM Verastem, Inc.
7.75
+2.11%
KURA Kura Oncology, Inc.
6.24
+3.65%
ATRA Atara Biotherapeutics, Inc.
6.73
-1.61%
ITOS iTeos Therapeutics, Inc.
8.41
+7.68%
FOLD Amicus Therapeutics, Inc.
6.42
-0.16%